Enterprise Value
1.523B
Cash
533.6M
Avg Qtr Burn
N/A
Short % of Float
14.30%
Insider Ownership
15.44%
Institutional Own.
92.36%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CART-ddBCMA (iMMagine-1) Details Multiple myeloma | Phase 2 Interim update | |
ACLX-001 (ARC-SparX program) Details Multiple myeloma | Phase 1 Interim update |